Tag Archives: MTC

PRNews

OpenEye Announces Pfizer To Adopt Orion Cloud Platform For Computational Chemistry

SANTA FE, New Mexico, Aug. 17, 2017 /PRNewswire/ — OpenEye Scientific Software, Inc., an innovative developer of molecular modeling and cheminformatics solutions, today announced that it has entered into an agreement with Pfizer Inc., to provide Orion, OpenEye’s new cloud platform, to the company’s Medicinal Sciences division.  Orion will equip chemists with all of OpenEye’s software, extensive tools for data visualization and communication, useful data sources and customizable, task-oriented workflows, all in a robust, scalable, cloud environment.

“We believe that Orion has the potential to revolutionize how computation is delivered to the pharmaceutical industry,” said Dr. Anthony Nicholls, CEO and founder of OpenEye Scientific Software, Inc. “Orion marries the immense resource of cloud computing services, with our insights, science and tools from two decades of helping customers. It continues and expands our tradition of computing at scale, reliable, predictive science and facilitating local innovation. As an open, collaborative platform for both industry and academia we think it can enhance the drug discovery process.”

“We look forward to implementing Orion’s workflow tools to help our efforts to deliver potential breakthrough therapies for patients,” said Enoch Huang, Executive Director of Computational Sciences at Pfizer.

About OpenEye

OpenEye has built a reputation as a scientific leader in the field of molecular design based on two decades of delivering useful applications and programming toolkits. Our scientific approach has focused on the power of molecular 3D structure to inform and guide, in particular via the concept of shape similarity. We have changed industry perception of what is possible with the speed, robustness and scalability of our tools and have recently built these into a ground-up, cloud-native platform, Orion. Combining unlimited computation and storage with powerful tools for data sharing, visualization and analysis in an open development platform, Orion offers unprecedented capabilities for drug discovery and optimization. OpenEye Scientific is a privately held company headquartered in Santa Fe, New Mexico, with offices in Boston, Massachusetts, Cologne, Germany, Strasbourg, France and Tokyo, Japan.  For further information on the company and its products, see www.eyesopen.com.

FOR ADDITIONAL INFORMATION

OPENEYE SCIENTIFIC SOFTWARE, INC.

Jeffrey Grandy, Vice President, Sales

+1 505-473-7385 x60

Email: sales@eyesopen.com

PRNews

Decision Resources Group Acquires Context Matters to Expand Global Market Access Intelligence Offerings

BURLINGTON, Massachusetts, Aug. 16, 2017 /PRNewswire/ — Decision Resources Group (DRG), the life sciences industry’s most trusted provider of market intelligence and global data products and services, today announced that it has completed the acquisition of Context Matters, the innovative data technology start-up that developed a first-of-its-kind global market access integrated data platform. Previously the lead investor in a Series B funding round for the startup last fall, DRG’s full acquisition and planned integration of Context Matters cements its position as the partner of choice for global market access data products, analytics, and strategic guidance.

The acquisition of Context Matters reinforces DRG’s commitment to providing a deep understanding of global market access landscapes which life sciences organizations can leverage to drive profitable asset management from development through commercialization. It will fortify DRG’s global market access portfolio by combining the novel Context Matters data model, which links global regulatory and health technology assessment data to detailed clinical trial data, with DRG’s existing suite of products and services.  The addition of Context Matters will result in a full service global market access and drug value navigation partner to the life sciences industry, with the flexibility to deliver solutions scaled to client needs and timing—from tactical target points to end-to-end enterprise strategy.

“There is an ever-rising demand to optimize global access to treatments for patients in therapy areas that continue to have unmet need. In our increasingly complex and cost-benefit driven markets, it is imperative for healthcare companies to build robust, evidence-based approaches to plan and prepare their assets for successful global market access,” says Peter Hempshall, Senior Vice President of DRG. “With the acquisition of Context Matters, DRG is pleased to welcome an experienced team of pioneering global market access experts. They have been at the forefront of compiling and connecting disparate forms of data to provide life sciences companies with the depth of data and direction needed to plan and implement successful access, reimbursement and asset valuation strategies for varied global markets.”

“Context Matters was created from the idea that data from market access and reimbursement can be used to inform clinical trial design,” explained Yin Ho, M.D., M.B.A., the Founder and CEO of Context Matters. “It has been extremely gratifying to watch Context Matters become a force to change the thinking of the pharmaceutical industry around how to use data to position and honestly evaluate the value of customers’ assets in a global marketplace,” said Dr. Ho. “We have been leaders in the industry and our vision will continue to live on in our products, services, and customers as we move forward with DRG.”

About Context Matters, Inc.

Context Matters modernizes and improves the process of valuing drug therapies, empowering life sciences organizations to achieve optimal reimbursement for their innovation. The Context Matters Market Access Platform (MAP) defines a new product category for global drug valuation — a configurable technology platform linking drug development and market data through a sophisticated model making comparative analysis and contextual views possible to establish reimbursement and market access. The MAP is a disruptive innovation that provides pharmaceutical and biotechnology companies direct access to the insights they need to inform key product development decisions and gain optimal reimbursement value. Visit ContextMatters.com for more information.

About Decision Resources Group

Decision Resources Group, a subsidiary of Piramal Enterprises Ltd., is the premier source for global healthcare data and market intelligence. A trusted partner for over 20 years, DRG helps companies competing in the global healthcare industry make informed business decisions. Organizations committed to the development and delivery of life-changing therapies rely on DRG’s in-house team of expert healthcare analysts, data scientists, and consultants for critical guidance. DRG products and services, built on extensive data assets and delivered by experts, empower organizations to succeed in complex healthcare markets. Please visit decisionresourcesgroup.com for more information.

For press inquiries, please contact Tori Gillern at tgillern@teamdrg.com.

PRNews

Vista Launches VTO, Providing High-end Health Care Services To High Net-worth Individuals In China

SHENZHEN, China, Aug. 11, 2017 /PRNewswire/ –To cater to the increasing demand for exclusive health care services among the Chinese high net-worth, Vista, a veteran with two decades of high-end medical service experience in China integrated its best medical resources and launched VISTA THE ONE (VTO), a private health care institution targeting high net-worth individuals and families.


VTO

China’s rapid economic development has created exponentially growing numbers of high net-worth individuals. The gradual aging of this group of people has opened the “private doctors” market in China. The targeted demographic of people is more willing to spend on decreasing their health risks in the future. Specifically, to reduce the uncertain threats on their accumulated wealth – the inheritance issues caused by sudden diseases has become one of their most pressing needs.

Yang Kaixiang, Chief Operating Officer of VTO said: “The significant advantages of VTO’s core services compared to the competitive market of “private doctors” lie in Vista’s unique position and experience. Having served China’s high-end community for over 20 years, Vista has absorbed the essence of high-end private doctor services from other countries. Vista has also accumulated affluent professional experience as well as gaining a profound understanding about the customers’ personalized needs. The highly customized service and products have been widely recognized by Vista customers.”

 “VTO provides its members exclusive healthcare services, for example, exclusive medical group, exclusive family follow up, 24/7 VIP hotlines”, added Yang. “In addition, standard VTO membership equips its owner global medical butler services, including top-tier doctors’ appointments around the world, VVIP services through the whole process and VIP priority access to any medical channels. VTO members are also entitled to Vista’s established world-wide emergency medical rescue service, namely the exclusive usage of Vista’s aviation medical plane.”

Besides the individual and family healthcare services for high-end VVIP customers, Vista operates the VTO member community collectively to build an ecosystem surrounding the idea of the “pan-health industry”, providing a communication platform for resource exchange, such as capital investment and business cooperation for elites.

In order to ensure that VTO members enjoy the high-end health services that matches their status, the conditions for joining are comparatively stricter, including no less than RMB 50 million net assets for an individual and no less than RMB 100 million net assets for families. VTO adopts an invitation only membership management model and applications are not accepted.

About Vista

Vista is the first medical institution to enter the “high-end medical” market in China. All its general doctors have more than 10 years of general practice training, with more than 20 years of practice experience. In 2016, Vista was named “The Most Popular Medical Institution” in China for embassies. Vista has signed up with more than 70 high-end commercial health insurance companies around the world, and has mature medical reception capabilities in 139 mainstream hospitals around the world. The Vista Air Rescue Team has accumulated more than 200 hours on its service record and is currently working as a sole medical partner in cooperation with the Chinese National Health Service Commission on the “One-Belt-One-Road” emergency rescue project, which provides Vista customers more effective medical protection in the countries along the belt and road.

View original content with multimedia:http://www.prnewswire.com/news-releases/vista-launches-vto-providing-high-end-health-care-services-to-high-net-worth-individuals-in-china-300503182.html

PRNews

Korea Institute of Science and Technology (KIST) Develops a New Drug for Alzheimer’s Disease

— Development of a new, innovative drug for Alzheimer’s disease overcoming the limits of existing medicines.

— Offering a new hope of developing a global cure for Alzheimer’s disease through technology transfer and clinical trial

SEOUL, South Korea, Aug. 9, 2017 /PRNewswire/ — As the world population is aging, the top priority of leading countries is to come up with solutions that can overcome dementia. Currently, a handful of anti-dementia drugs are used. But most of them just temporarily alleviate symptoms. Recently, there has been a series of failures of global candidate drugs that have been developed based on the conventional treatment mechanism. Due to the failures, now is a good time to develop a drug based on the root cause of dementia.

Through a fruitful collaboration, scientists at KIST, Ki-Duk Park, C. Justin Lee, and Ae-Nim Pae, developed a drug candidate for dementia with excellent drug-like properties and efficacy. The drug candidate (KDS2010) was based on the previous findings that reactive astrocytes, commonly found in the brain of Alzheimer’s patients, generate and secrete GABA, an inhibitory neurotransmitter, causing memory impairment and cognitive impairment (Nature Medicine, 2014).

This synthetic drug developed by the researchers is a substance that can reduce the amount of abnormally produced GABA. It is a drug candidate that can dramatically improve memory and cognitive impairment of Alzheimer’s disease patients.

* GABA: One of the transmitters of the central nervous system of mammals with strong inhibitory effect on neuronal excitability.

Researchers dissolved the drug in water and fed the mice that are genetically modified to mimic Alzheimer’s disease. They conducted Morris water maze and passive avoidance experiments to check the mice’s memory. They found that cognitive functions of the Alzheimer’s mice returned to the normal state. Furthermore, long-term administration of a low dose (1mg/kg) of the drug led to a long-lasting improvement in cognitive functions, even up to 4 weeks of treatment. This is in great contrast to the existing drugs, whose early efficacy is excellent but long-term administration has low efficacy. Furthermore, according to the results of verifying ADME/Tox, the drug candidate effectively transferred to the brain through oral intake and had drug-like properties without biotoxicity and any side effects on other nervous system.


The ability of candidate drug(KDS2010) to restore neuronal spike probabilities compared to pre-existing drug

This drug candidate provides a fundamental treatment option for cognitive function disorders through an entirely new treatment regime. So far it has been tested for long-term efficacy and toxicity. Currently, non-clinical trials are conducted at the GLP level. This could turn out to be a next-generation global drug for Alzheimer’s disease through immediate clinical trials.

On the 31st of May, Byeonggwon Lee, the president of KIST and Sangmin Park, CEO of MegaBioWood, an affiliate of KEMIMEDI(CEO, Geonseop Choi) had a signing ceremony for the technology transfer on “Drug Candidate for Alzheimer’s disease” at the KIST Seoul Campus. The total amount of the technology transfer contract was for 6 million US dollars, including $500,000 upfront payment and 5.5 million US dollars as a milestone technology payment. The running royalty was signed for 3% of net sales.

KIST (Korea Institute of Science and Technology)

Dr. C Justin Lee
Tel. +82-2-958-6940
e-mail. cjl@kist.re.kr

Dr. Ki-Duk Park
Tel. +82-2-958-5132
e-mail. kdpark@kist.re.kr

View original content with multimedia:http://www.prnewswire.com/news-releases/korea-institute-of-science-and-technology-kist-develops-a-new-drug-for-alzheimers-disease-300501300.html

PRNews

European Patent Office to Grant Merck’s Patent Application for CRISPR Technology

– Patent application covers integration of an external DNA sequence into the chromosome of eukaryotic cells using CRISPR

– Related patent application recently awarded in Australia; similar patents pending in other countries, favourable outcomes anticipated

DARMSTADT, Germany, Aug. 3, 2017 /PRNewswire/ — Merck, a leading science and technology company, today announced the European Patent Office (EPO) has issued a “Notice of Intention to Grant” for Merck’s patent application covering the company’s CRISPR technology used in a genomic integration method for eukaryotic cells.


Merck’s patent application covers integration of an external DNA sequence into the chromosome of eukaryotic cells using CRISPR. The patent will give Merck’s CRISPR genomic integration technology broad protection, further strengthening the company’s patent portfolio.

The patent will provide Merck’s CRISPR genomic integration technology with broad protection, further strengthening the company’s patent portfolio. A related patent was approved in Australia in June 2017.  Merck anticipates favourable outcomes in other countries as well, because many patent offices worldwide consider the status of related European cases to be highly relevant to the decision to grant patents.

“This is a significant and exciting decision by the EPO, and we view this announcement as recognition of Merck’s important contributions to the genome-editing field,” said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. “This patent provides protection for our CRISPR technology, which will give scientists the ability to advance treatment options for the toughest medical challenges we face today.”

With Merck’s CRISPR genomic integration technology, scientists can replace a disease-associated mutation with a beneficial or functional sequence – a method important for creation of disease models and gene therapy. Scientists can also use the method to insert transgenes to enable basic research, using the technology to label endogenous proteins for visual tracking within cells, for example.

This patent application is one of Merck’s multiple CRISPR patent filings since 2012. In May 2017, Merck introduced an alternative CRISPR genome-editing method called proxy-CRISPR. Unlike other systems, the proxy-CRISPR technique allows cutting of previously unreachable cell locations, making CRISPR more efficient, flexible and specific—giving researchers more experimental options.

Merck, with its 14-year history in the genome-editing field, was the first company to offer custom biomolecules globally for genome editing (TargeTron™ RNA-guided group II introns and CompoZr™ zinc finger nucleases), driving widespread adoption by researchers. In collaboration with the Wellcome Trust Sanger Institute, Merck was also the first company to manufacture arrayed CRISPR libraries covering the entire human genome, allowing researchers to explore more questions about disease and develop cures faster. Availability of arrayed CRISPR libraries is an important advancement in genome editing and reinforces the company’s leadership position.

The company also supports development of gene- and cell-based therapeutics and manufactures viral vectors, in addition to conducting basic genome-editing research. In 2016, Merck launched an initiative to advance research in novel treatment modalities, from genome editing to gene medicine manufacturing, through a dedicated team and enhanced resources. This venture further solidifies the company’s commitment to the genome-editing field.

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of €15 billion in 66 countries.

Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the “Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

PRNews

Frost & Sullivan Acclaims Shimadzu for Delivering a Product Line of Versatile and Innovative Radiography Solutions

Shimadzu’s products utilize advanced robotic capabilities and next-generation digital imaging technologies

LONDON, Aug. 3, 2017 /PRNewswire/ — Based on its recent analysis of the general radiography market, Frost & Sullivan recognizes Shimadzu Corporation with the 2017 Global Frost & Sullivan Award for Product Line Strategy Leadership. Constant innovations and upgrades to Shimadzu’s radiography product portfolio have ensured that the products stay relevant and in high demand in an evolving radiography market. Its comprehensive product range enhances automation, efficiency, image quality, and overall clinical value by enabling flexible positioning, reduced radiation dose, and versatility in viewing bone and soft tissue images.

Shimadzu has the entire range of general radiography solutions, from fixed ceiling-mounted to floor-mounted systems and mobile X-ray solutions, with or without one to two arms. These are all available all in entry-level to high-end configurations. In 2016, it introduced new technologies such as digital multi-slice tomography with flexible positioning to offer a view of oblique cross sections of the spine and hip joints. Other products include:

  • SONIALVISION G4, a fluoroscopy product with multi-functionality features
  • RADspeed Pro EDGE package, a high-performance general radiography equipment
  • MobileDaRt Evolution MX7 Version, mobile X-ray with digitization features.

RADspeed Pro EDGE and MobileDaRt Evolution MX7 have already been adopted by more than 100 hospitals worldwide within a year of their introduction.

“In response to customer demand, Shimadzu introduced a sophisticated, remote-controlled, auto-positioning feature in the RADspeed Pro EDGE package. This feature helps the radiographer effortlessly position the tube and fine-tune this positioning to improve patient safety and reduce radiation dose,” said Frost & Sullivan Consultant Poornima Srinivasan. “Similarly, it incorporated removable grids to lower radiation exposure during pediatric imaging, and a dose area product meter on the collimator to measure the dose of radiation the patient is exposed to.”

Shimadzu’s products have proven their utility in guiding hospitals towards the era of value-based healthcare. They achieve that by incorporating a host of novel features and technologies.

  • The RADspeed Pro EDGE employs cutting-edge technologies like tomosynthesis, speed stitch, and dual energy subtraction. Tomosynthesis combines cone-beam computed tomography (CT) reconstruction with digital image processing so that any number of cross-sectional images can be obtained. The systems also incorporate ‘T-smart,’ the metal artifact reduction technology that decreases metal artifacts in orthopedic patients. Additionally, it uses speed stitch technology, which combines multiple images that are captured while the X-ray tube is in motion at various angles. Finally, its dual energy subtraction, imaging algorithm, couples with low and high voltages to offer images of soft tissue and bone images separately.
  • SONIALVISION G4 is capable of a wide range of examinations and is ideal for inter-departmental shared services. The field of view (FOV) flat panel detector (FPD) is available in five sizes and provides an extensive imaging area, ultra-high definition and dynamic images, less radiation exposure, a ceiling-mounted telescopic arm, and a wall stand with a portable FPD. It incorporates technologies such as:
    • The SUREengine-Advance, an image processing technology that delivers quality fluoro and radiography images
    • SLOT Advance, an optimal technology for long-view images with a minimal X-ray dose
    • T-smart, the latest tomosynthesis technology that aids in iterative reconstruction with metal artifact suppression
  • The MobileDaRt Evolution MX7 Version incorporates a large LCD monitor and LED collimator light that increases brightness up to 40% and saves electricity by 80% when compared to its competing products. It also has a user-friendly design with wireless capability, which allows it to extend its scope of application.

“Shimadzu has leveraged the expertise of key opinion leaders (KOLs), designed training and educational programs, expanded geographically, and made the most of cross-selling opportunities in line with its business goals,” noted Ms. Srinivasan. “Additionally, it has partnered with universities to optimize the existing systems and develop further innovations and efficiencies. Shimadzu’s discussions with international channels, and focus on gathering input from healthcare professionals have played a huge role in its development of unique products and provision of a rich customer experience.”

Each year, Frost & Sullivan presents this award to the company that has developed a comprehensive product line that caters to the breadth of the market it serves. The award recognizes the extent to which the product line meets customer base demands, the overall impact it has in terms of customer value, as well as increased market share.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Shimadzu Corporation

Shimadzu Corporation has remained committed to commercializing cutting-edge technology and providing it to customers in a wide array of industries for more than 140 years. Our brand statement, “Excellence in Science”, reflects our desire and attitude to diligently respond to customers’ requirements by offering superior, world-class technologies indispensable for analytical and measuring instruments, medical systems, aircraft equipment and industrial machinery in the area of human health, safety and security of society and advancement of industry. In the ever-changing landscape of challenges of society, Shimadzu aims to partner with customers to meet their needs with unique technologies and solutions.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:

Ana Arriaga
P: 210.247.3823
F: 210.348.1003
E: ana.arriaga@frost.com

PRNews

Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Solution, CytoSorb®

By controlling dangerous inflammation, CytoSorb® is enabling superior outcomes in critically-ill patients, with reduced overall costs of intensive care in its sights

LONDON, Aug. 2, 2017 /PRNewswire/ — Based on its recent analysis of the blood purification market, Frost & Sullivan recognizes CytoSorbents Corporation with the 2017 Global Frost & Sullivan Award for Product Leadership. CytoSorbents’ deceptively simple yet powerful blood purification therapy, CytoSorb®, helps critical care physicians and heart surgeons control deadly inflammation in their patients. CytoSorb® actively reduces circulating cytokines, toxins, and other substances in blood that feed and perpetuate uncontrolled inflammation in a diverse set of medical emergencies such as sepsis, infection, trauma, cardiac surgery, and liver failure. Its ultimate aim is to prevent a patient from being killed by his or her own out-of-control immune response.

“There were many factors that led to our selection of CytoSorb® for this year’s Global Product Leadership Award,” said Frost & Sullivan Research Analyst Aish Vivek. “Among the most important was the recognition that this innovative product is surprisingly well-positioned to help solve two long-standing, difficult, and tightly linked fundamental problems with hospital medicine today. These include the high rates of death from common critical illnesses such as sepsis that have no approved treatment, and the resulting staggering costs and losses in critical care that are financially crippling hospital networks and healthcare systems throughout the world.”

“Further strengthening CytoSorb’s position is the scarcity of viable competition in the lucrative and vast global critical care and cardiac surgery markets, the strong physician usage and revenue growth, and the external validation from well-respected industry partners, such as Fresenius Medical Care and Terumo Cardiovascular, and government funding agencies.  As a high margin, single-use product that works with existing blood pumps in hospitals, CytoSorb® also has an attractive business model that is expected to drive early and significant profitability of the company.”

“CytoSorb® has taken blood purification as a means to control inflammation to the next level, with its patented blood compatible, porous polymer bead technology,” concluded Aish Vivek. “This best-of-breed solution is approved in the European Union and has been used in more than 23,000 treatments to help save many lives across 44 countries.  As the clinical experience and scientific publications continue to grow, we predict that CytoSorbents, through CytoSorb®, will solidify its leadership in critical care and cardiac surgery, with expansion into other promising fields such as cancer immunotherapy, and treatment of chronic illness. We are also excited to follow along as CytoSorbents initiates a registration trial later this year that targets U.S. FDA approval.”

Overall, for positioning itself strongly with its CytoSorb® therapy and serving a wide array of applications, Frost & Sullivan is pleased to present CytoSorbents with the 2017 Global Frost & Sullivan Award for Product Leadership in the blood purification market.

Each year, Frost & Sullivan presents this award to the company that has developed a product with innovative features and functionality, gaining rapid acceptance in the market. The award recognizes the quality of the solution and the customer value enhancements it enables.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About CytoSorbents Corporation

CytoSorbents Corporation (NASDAQ: CTSO) is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb®, is approved in the European Union with distribution in 44 countries worldwide, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, complications of surgery, cancer immunotherapy, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. In 2017, the company plans to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval.  CytoSorb® has been used safely in more than 23,000 human treatments to date.

CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding in excess of $19 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents, multiple international patents, and many applications pending worldwide.  Products under development include CytoSorb-XL™, HemoDefend™, VetResQ™, ContrastSorb, DrugSorb, and others.  Visit www.cytosorbents.com and www.cytosorb.com

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:

Aish Vivekanandan
Phone: 210-477-8495
Email: aish.vivekanadan@frost.com

PRNews

OrthoAccel Technologies, Inc. Names Orthodontic and Dental Industry Executive David Josza as CEO

HOUSTON, July 26, 2017 /PRNewswire/ — OrthoAccel® Technologies, Inc. announces that its board of directors has named David Josza, an orthodontic and dental industry senior executive with more than 25 years of experience, as CEO effective August 1, 2017. A privately owned medical technology start-up, OrthoAccel recently launched its third-generation vibratory orthodontic device AcceleDent® Optima™ that enables orthodontists to achieve more predictable outcomes. AcceleDent Optima is an FDA-cleared, Class II medical device that is clinically shown in randomized control trials to speed up orthodontic treatment by as much as 50 percent while reducing discomfort by up to 71 percent during treatment.

“OrthoAccel is a market leader in accelerated orthodontic technology and I am delighted to lead the company’s next phase of growth and innovation,” said Josza. “This is an exciting stage in OrthoAccel’s trajectory and, based on the feedback of orthodontists and patients who have experienced the new AcceleDent Optima, there is significant opportunity for growth ahead for this best-in-class treatment technology.”

Josza most recently served as corporate vice president and general manager for Zimmer Biomet Dental, a leading global manufacturer of musculoskeletal devices. He joined Zimmer in 2015 when the company acquired his previous firm, Biomet, Inc., and Josza was tapped to lead the complex acquisition integration. Among his accomplishments, he successfully implemented synergistic cost-saving initiatives and cross-selling opportunities that yielded significant profit increases and growth.

Prior to the acquisition, Josza had a 14-year career at Biomet 3i, a global implant and oral reconstructive supplier, most recently serving as vice president of the Americas. As a member of the executive board, he was responsible for developing and delivering the company’s annual strategic plan.

Additional accomplishments at Biomet included developing and leading a variety of significant revenue growth initiatives, including capturing the market leader position in Latin America. Another key accomplishment was the commercialization of a new digital product line, with a specialized sales team and a technical service support function that grew incremental revenue by $2 million in its first year.

In addition to his leadership roles at Zimmer and Biomet, Josza’s in-depth experience includes previous business development, strategic planning and management responsibilities at Henry Schein, Inc. and Stryker Corporation.  

“We are excited to welcome David and recognize that his in-depth experience in dental and medical industries, combined with his many successes as a strategist and business developer, provide an excellent leadership platform for his role at OrthoAccel Technologies,” said Brian R. Smith, chairman of OrthoAccel’s board of directors and managing director of S3Ventures.

The leader in accelerated orthodontics, OrthoAccel has received numerous business and medical design awards that reflect the company’s success in commercializing its patented SoftPulse Technology® for clinical application. AcceleDent has been recognized as the preferred accelerated orthodontic treatment solution by orthodontists participating in surveys conducted by industry journals Orthotown and the Journal of Clinical Orthodontics.

For more information about OrthoAccel and the company’s innovative orthodontic solutions, visit AcceleDent.com.

About OrthoAccel® Technologies, Inc.
OrthoAccel® Technologies, Inc. is a privately owned medical device company engaged in the creation, manufacturing, marketing and sales of innovative solutions that enhance dental care and orthodontic treatment. Among the company’s innovations is AcceleDent® Optima™, an FDA-cleared, Class II medical device that employs patented SoftPulse Technology® that is demonstrated to speed up bone remodeling. These safe and gentle vibrations accelerate tooth movement by as much as 50 percent and reduce discomfort associated with orthodontic treatment by up to 71 percent. Leading orthodontists from around the world report increased mechanical efficiency with orthodontic appliances and improved predictability of clinical outcomes with AcceleDent.  OrthoAccel, the Leader in Accelerated Orthodontics, is ranked on Deloitte’s 2016 Technology Fast 500 as one of the fastest growing companies in North America. OrthoAccel is based in Houston, Texas and maintains a global presence through its EMEA office in Essen, Germany. To learn more about OrthoAccel’s focus on improving the journey to healthy, beautiful smiles, visit AcceleDent.com.

Source: OrthoAccel Technologies, Inc.

PRNews

U.S. FDA Determines Celliant (R) Responsive Textile Products Meet Criteria as Medical Devices and General Wellness Products

– Hologenix, LLC’s technology is first of its kind to secure joint FDA designations 

– Celliant-engineered products clinically proven to promote increased localized blood flow

– FDA determination to usher in new era of performance fabrics, responsive textiles

LOS ANGELES, July 25, 2017 /PRNewswire/ — Hologenix, LLC, maker of Celliant, the world’s most advanced, clinically tested responsive textile technology, announced today that the U.S. Food and Drug Administration (FDA) has determined Celliant products are medical devices and general wellness products, as defined in Section 201(h) of the Federal Food, Drug and, Cosmetic Act. According to the FDA, Celliant products were determined to be medical devices because they temporarily promote increased local blood flow at the site of application in healthy individuals.


PureCare Elements: Lumen® Premium Celliant® Sheet Set: The first linen collection that uses Celliant to increase comfort and promote faster recovery while you sleep.

SIMA award winner, Xcel Infinity Comp TDC Full Suit with Celliant: Uses Celliant to create the warmest wetsuit lining so you can surf longer and recover faster.

ISPO award winner, Tecnica Mach 1 Pro Women Ski Boot: A ski boot made for women by women that uses Celliant and Lambswool Heat from Imbotex in its lining to address women’s specific needs for warmth, comfort and performance on and off the slope. Release date: Fall 2017

Salewa Puez TirolWool Celliant Half Zip Jacket: Bends TirolWool, naturally warm, breathable and hydrophobic insulation from Imbotex, with Celliant to keep outdoor enthusiasts energized and warm all day long. Release date: Fall 2017

“Celliant-engineered products are the first of their kind that the FDA has designated as medical devices,” said Seth Casden, Hologenix CEO. “Our technology can be used in everyday products — t-shirts, clothing, bedding, even airplane seats — to create an increase in local blood flow thereby increasing energy, boosting performance and speeding muscle recovery.”

“We believe that Celliant is a truly disruptive technology that has transformational applications for textiles,” Casden said. “We’re currently evaluating additional applications of Celliant in the healthcare space, where, for example, people who suffer from diabetes might benefit from increased blood flow to body tissue.”

Celliant-engineered products harness and recycle the natural heat emitted by human beings to boost performance and rebuild and recharge the human body after physical activity and while you sleep. Celliant is made of a patented blend of thermo-reactive minerals infused into the core of fiber used to create all types of textiles and fabrics so it does not wash or wear out. Products made with Celliant fabric absorb and convert body heat into infrared energy (IR) that is recycled back into skin and tissue in a safe, natural way. IR is a vasodilator, increasing blood flow to tissue and muscles throughout the body, which delivers vital nutrients and oxygen to the cells. The effect is clinically proven to help the body:

  • increase energy, endurance, stamina and performance,
  • recover faster from physical activity,
  • promote restful sleep and increased comfort.

Celliant is used in a diverse range of textiles and applications – apparel, bedding, wetsuits and veterinary products, including:

  • SIMA award winner, Xcel Infinity Comp TDC Full Suit with Celliant which uses Celliant to create the warmest wetsuit lining so you can surf longer and recover faster;
  • Salewa Puez TirolWool Celliant Half Zip Jacket that blends TirolWool, naturally warm, breathable and hydrophobic insulation from Imbotex, with Celliant to keep outdoor enthusiasts energized and warm all day long. Release date: Fall 2017;
  • ISPO award winner, Tecnica Mach 1 Pro Women Ski Boot, a ski boot made for women by women that uses Celliant and Lambswool Heat from Imbotex in its lining to address women’s specific needs for warmth, comfort and performance on and off the slope. Release date: Fall 2017;
  • PureCare Elements: Lumen® Premium Celliant® Sheet Set, the first linen collection that uses Celliant to increase comfort and promote faster recovery while you sleep.

“Science has shown that infrared energy increases blood flow, improves muscle recovery and reduces long-term pain,” said Dr. Michael R Hamblin, principal investigator at the Wellman Center for Photomedicine at Massachusetts General Hospital. “The FDA’s determination of Celliant products as medical devices and general wellness products will likely spur interest in infrared technologies and further development of garments and wraps that can positively impact people’s well-being.”

Celliant has been extensively researched, developed and clinically tested for both durability and effectiveness. Prominent institutions have conducted nine clinical trials to evaluate Celliant’s performance including University of California Irvine, University of Calgary, UCI Long Beach Veterans Affairs Medical Center, Texas A&M University, Loyola University Chicago and Exponent. Celliant technology has been shown to increase tissue oxygen levels by eight percent at the site of applicationi. Click here for NIH independent study on the benefits of IR on recovery.

About Celliant®
Celliant is a revolutionary, patented technology that harnesses and recycles the body’s natural energy through the medium of fibers. Celliant’s applied science utilizes a blend of minerals and proprietary ingredients that are embedded into the core of the fiber. Use of products containing this technology has been clinically proven to enhance tissue oxygen levels, improve athletic performance, sleep quality, health and wellness. Fibers, yarns and fabrics with Celliant technology can be found in some of the world’s most recognized name brands. For more information, visit www.celliant.com.  

About Hologenix, LLC
Founded in 2002, Hologenix, LLC, maker of Celliant technology, is committed to creating, developing and bringing to market products that enhance people’s lives through new materials. They strive to deliver the future of healthy innovation through a variety of consumer categories. In addition to the United States, Celliant is designated as a Class I medical device in Canada, European Union, Australia and New Zealand. The Company continues to explore new territories and is currently running FDA-focused, clinical trials to expand into the medical product arena.

i Dr. Ian Gordon – University of CA, Irvine, Effect of Garment with 42% Celliant Fiber on TCP02 Levels and Grip Strength in Healthy Subjects. 2010

Contact: Julia Moore, +1-212-445-8160, Julia.Moore@webershandwick.com

Photo – http://mma.prnewswire.com/media/538683/PureCare_Sheets.jpg
Photo – http://mma.prnewswire.com/media/538684/Xcel_Infinity_Comp_Full_Suit.jpg
Photo – http://mma.prnewswire.com/media/538685/Tecnica_Mach_1_Pro_Women_Ski_Boot.jpg
Photo – http://mma.prnewswire.com/media/538686/Salewa_Puez_TirolWool_Celliant_Half_Zip_Jacket.jpg
Logo – http://mma.prnewswire.com/media/538687/Celliant_Logo.jpg 

PRNews

CROMSOURCE Celebrates Its 20th Anniversary

VERONA, Italy, July 18, 2017 /PRNewswire/ —

CROMSOURCE marks its twentieth anniversary of providing high quality clinical research services and exceptional customer support to our global pharmaceutical, biotechnology, and medical device clients.

For the last twenty years, CROMSOURCE has been a valued partner to hundreds of global clients, having provided services for more than 3000 clinical trials across a number of important areas. Much of the work which we have performed has led to the approval and marketing of life-changing and life-saving medical products across the globe.

“CROMSOURCE’s twentieth anniversary is an exciting milestone for our company! When I started this adventure, one goal was that CROMSOURCE would become an international provider serving customers all over the world. It is with great pride that today we can say that we have accomplished that ambition,” said Dr. Oriana Zerbini, founder and CEO of CROMSOURCE.

“Moreover, CROMSOURCE could only have achieved such success with the involvement of its employees and clients. We are proud of having the confidence of our clients and being a trusted partner for their product development programs. And, of course, our employees are the heart of our growth and success. Their diligence, motivation, passion, and unwavering dedication have all been a source of inspiration for reaching this important milestone,” continued Dr. Zerbini.

“Looking toward the future, we recognize the need to evolve as the world, and our industry, continues to experience rapid change. Thanks to our talented professionals and flexible approach to performing clinical research services, we are uniquely positioned to be the ideal partner for the most complex and challenging development programs. We also believe the best for CROMSOURCE and our clients and employees is yet to come based on our existing and growing pipeline of opportunities ranging from early phase through post-marketing studies across an important array of therapeutic areas, medical devices, and rare diseases,” said Dr. Troy McCall, Chief Operating Officer stated.

About CROMSOURCE     

CROMSOURCE is an ISO-certified, international provider of outsourced services to the pharmaceutical, biotechnology, and medical device industries, specialized in clinical development and staffing solutions. We  offer a flexible approach to ensure our clients’ unique needs are supported. CROMSOURCE is unparalleled in offering an end-to-end guarantee covering trial timelines, enrollment, and price.  CROMSOURCE operates offices across all regions of Europe and North America. For more information, visit http://www.cromsource.com.

Contact Info
Margherita Mosconi
margherita.mosconi@cromsource.com
+39-045-82-22-811